Dexcom (NSDQ:DXCM) shares are up more than 13% today — a day after Q2 results that topped the consensus forecast.
The San Diego-based continuous glucose monitor developer also announced continued clinical and regulatory progress with its next-gen G7, though the timing of a U.S. G7 release is still an open question.
Dexcom posted profits of $62.9 million, or 63¢ per share, on sales of $595.1 million for the three months ended June 30, 2021, for a 35.9% bottom-line gain on sales growth of 31.7%.
Get the full story at our sister site, Drug Delivery Business News.
This article originally ran on the evening of Thursday, July 29. Updated July 30 with the next-day stock price.